Hui Shao1, Vivian Fonseca2, Charles Stoecker1, Shuqian Liu1, Lizheng Shi3. 1. Department of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, Suite 1900, New Orleans, LA, 70112, USA. 2. School of Medicine, Tulane University, New Orleans, LA, USA. 3. Department of Global Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, 1440 Canal Street, Suite 1900, New Orleans, LA, 70112, USA. lshi1@tulane.edu.
Abstract
BACKGROUND: There is an urgent need to update diabetes prediction, which has relied on the United Kingdom Prospective Diabetes Study (UKPDS) that dates back to 1970 s' European populations. OBJECTIVE: The objective of this study was to develop a risk engine with multiple risk equations using a recent patient cohort with type 2 diabetes mellitus reflective of the US population. METHODS: A total of 17 risk equations for predicting diabetes-related microvascular and macrovascular events, hypoglycemia, mortality, and progression of diabetes risk factors were estimated using the data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (n = 10,251). Internal and external validation processes were used to assess performance of the Building, Relating, Assessing, and Validating Outcomes (BRAVO) risk engine. One-way sensitivity analysis was conducted to examine the impact of risk factors on mortality at the population level. RESULTS: The BRAVO risk engine added several risk factors including severe hypoglycemia and common US racial/ethnicity categories compared with the UKPDS risk engine. The BRAVO risk engine also modeled mortality escalation associated with intensive glycemic control (i.e., glycosylated hemoglobin < 6.5%). External validation showed a good prediction power on 28 endpoints observed from other clinical trials (slope = 1.071, R2 = 0.86). CONCLUSION: The BRAVO risk engine for the US diabetes cohort provides an alternative to the UKPDS risk engine. It can be applied to assist clinical and policy decision making such as cost-effective resource allocation in USA.
BACKGROUND: There is an urgent need to update diabetes prediction, which has relied on the United Kingdom Prospective Diabetes Study (UKPDS) that dates back to 1970 s' European populations. OBJECTIVE: The objective of this study was to develop a risk engine with multiple risk equations using a recent patient cohort with type 2 diabetes mellitus reflective of the US population. METHODS: A total of 17 risk equations for predicting diabetes-related microvascular and macrovascular events, hypoglycemia, mortality, and progression of diabetes risk factors were estimated using the data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (n = 10,251). Internal and external validation processes were used to assess performance of the Building, Relating, Assessing, and Validating Outcomes (BRAVO) risk engine. One-way sensitivity analysis was conducted to examine the impact of risk factors on mortality at the population level. RESULTS: The BRAVO risk engine added several risk factors including severe hypoglycemia and common US racial/ethnicity categories compared with the UKPDS risk engine. The BRAVO risk engine also modeled mortality escalation associated with intensive glycemic control (i.e., glycosylated hemoglobin < 6.5%). External validation showed a good prediction power on 28 endpoints observed from other clinical trials (slope = 1.071, R2 = 0.86). CONCLUSION: The BRAVO risk engine for the US diabetes cohort provides an alternative to the UKPDS risk engine. It can be applied to assist clinical and policy decision making such as cost-effective resource allocation in USA.
Authors: M Charokopou; P McEwan; S Lister; L Callan; K Bergenheim; K Tolley; R Postema; R Townsend; M Roudaut Journal: Diabet Med Date: 2015-04-30 Impact factor: 4.359
Authors: Andrew J Karter; Assiamira Ferrara; Jennifer Y Liu; Howard H Moffet; Lynn M Ackerson; Joe V Selby Journal: JAMA Date: 2002-05-15 Impact factor: 56.272
Authors: Andrew J Palmer; Stéphane Roze; William J Valentine; Michael E Minshall; Clarice Hayes; Alan Oglesby; Giatgen A Spinas Journal: Curr Med Res Opin Date: 2004-08 Impact factor: 2.580
Authors: Hertzel C Gerstein; Matthew C Riddle; David M Kendall; Robert M Cohen; Robin Goland; Mark N Feinglos; Julienne K Kirk; Bruce P Hamilton; Faramarz Ismail-Beigi; Patricia Feeney Journal: Am J Cardiol Date: 2007-04-19 Impact factor: 2.778
Authors: Laura N McEwen; Andrew J Karter; Beth E Waitzfelder; Jesse C Crosson; David G Marrero; Carol M Mangione; William H Herman Journal: Diabetes Care Date: 2012-03-19 Impact factor: 19.112
Authors: Michael Willis; Christian Asseburg; April Slee; Andreas Nilsson; Cheryl Neslusan Journal: Pharmacoeconomics Date: 2021-02-13 Impact factor: 4.981
Authors: Amir Razaghizad; Emily Oulousian; Varinder Kaur Randhawa; João Pedro Ferreira; James M Brophy; Stephen J Greene; Julian Guida; G Michael Felker; Marat Fudim; Michael Tsoukas; Tricia M Peters; Thomas A Mavrakanas; Nadia Giannetti; Justin Ezekowitz; Abhinav Sharma Journal: J Am Heart Assoc Date: 2022-05-16 Impact factor: 6.106
Authors: Matthew W Segar; Kershaw V Patel; Muthiah Vaduganathan; Melissa C Caughey; Byron C Jaeger; Mujeeb Basit; Duwayne Willett; Javed Butler; Partho P Sengupta; Thomas J Wang; Darren K McGuire; Ambarish Pandey Journal: Diabetologia Date: 2021-03-13 Impact factor: 10.122
Authors: Zhuo T Su; Jose Bartelt-Hofer; Stephen Brown; Elisheva Lew; Luc Sauriol; Lieven Annemans; Daniel T Grima Journal: Pharmacoecon Open Date: 2020-03
Authors: Sharen Lee; Jiandong Zhou; Keith Sai Kit Leung; William Ka Kei Wu; Wing Tak Wong; Tong Liu; Ian Chi Kei Wong; Kamalan Jeevaratnam; Qingpeng Zhang; Gary Tse Journal: BMJ Open Diabetes Res Care Date: 2021-06